In re: Ekwuribe et al. Serial No.: to be assigned Filed: concurrently herewith

Page 2 of 4

Cont

p is a number from 1 to the maximum number of covalent bonding sites at which  $-[(H-H'_q)-L_o]$  can form a bond with D.

51. (New) The drug-oligomer conjugate of Claim 50, wherein H, H' and L are selected and arranged such that the drug-oligomer conjugate is amphiphilic.

52. (New) The drug-oligomer conjugate of Claim 56, wherein H is a PEG polymer having from 2 to 8 PEG units.

53. (New) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having from 2 to 7 PEG units.

54. (New) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 3 PEG units.

55. (New) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 4 PEG units.

7
56. (New) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 5 PEG units.

(New) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 6 PEG units.

(New) The drug-oligomer conjugate of Claim 50, wherein H' is a hydrophilic moiety selected from the group consisting of straight or branched PEG polymers and sugars.

59. (New) The drug-oligomer conjugate of Claim 50, wherein H' is a straight PEG polymer.





In re: Ekwuribe et al.

Serial No.: to be assigned

Filed: concurrently herewith

Page 3 of 4

y

60. (New) The drug-oligomer conjugate of Claim 59; wherein the PEG polymer has from 1 to 130 PEG units.

(New) The drug-oligomer conjugate of Claim 59, wherein the PEG polymer has from 1 to 100 PEG units.

52. (New) The drug-oligomer conjugate of Claim 50, wherein L is a lipophilic moiety selected from the group consisting of alkyl moieties, cholesterol, and fatty acid moieties.

(New) The drug-oligomer conjugate of Claim 50, wherein L is an alkyl moiety.

4. (New) The drug-oligomer conjugate of Claim 50, wherein L is cholesterol.

(New) The drug-oligomer conjugate of Claim 50, wherein L is a fatty acid moiety.

(New) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 2 and 28 carbon atoms.

(New) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 12 and 22 carbon atoms.

(New) The drug-oligomer conjugate of Claim 50, wherein D is insulin or insulin lispro.

69. (New) The drug-oligomer conjugate of Claim 50, wherein the H'-L bond is non-hydrolyzable.

and by

